Watch this space 👀 CheckMate 816 neoadjuvant results coming to a conference near you soon! Great to work with Drs. Chaft, Sepesi and Shyr on this review, hopefully it will need updating very frequently as new therapies emerge! #LCSM

A study of almost 10,000 patients with prosthetic joint infections found NO ASSOCIATION with recent dental procedures. This is the largest study to support ADA’s recommendation AGAINST antibiotic prophylaxis prior to dental visits in patients with prosthetic joints #medtwitter

Excited to share our work in Cindy Sears lab on Fusobacterium nucleatum in colon cancer mouse models, now available in mBio. This oral commensal is frequently enriched in colon tumors, but the jury is still out as to its role in tumorigenesis. journals.asm.org/doi/10.1128/mb…

Have you compared your calendar to your CV lately, #AcademicTwitter? If meetings (one on one or group) are repeating on your calendar but are not represented on your CV, then maybe one needs fixing. Align your time.

Any colleagues (med onc/rad onc/thoracic surg) who would like the data from the #AACR21 & #ASCO21 presentations & FDA label for purposes of clinical discussion about this new approval please shoot a direct message to me with your email or other contact #LCSM

Today, CheckMate 816, a phase 3 trial of neoadjuvant chemo + nivolumab immunotherapy was published i - this was a global effort to improve the lives of pts dealing with newly diagnosed surgical lung cancer. nejm.org/doi/full/10.10…

What an outstanding symposium on NeoAdjuvant Immunotherapy! #AACR22 #AACR2022. One of the best sessions I’ve seen in recent years. Patrick Forde 🇮🇪 Sara Tolaney Lizzy Smyth 🇮🇪. I would propose that Ireland should also claim Dr Tolaney!

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | NEJM nejm.org/doi/full/10.10… Grateful for the opportunity to contribute to this effort and for amazing collaboration at Hopkins and across the globe! Patrick Forde Jonathan Spicer MD PhD bet9 优德体育 足球 速8体育 彩金 江山美景图 彩娱乐 AB视讯 Hopkins Surgery

Great to chat with Dr. Bill Nelson, cancer center director (and former serious football - soccer for North Americans in audience! - player) about the exciting developments this week in immunotherapy for stage 1-3 lung cancer with the CheckMate816 trial now published! #lcsm

If you're an early career researcher studying the microbiome, consider applying for a grant from Biocodex Microbiota Institute. Link here: biocodexmicrobiotafoundation.com/national-call-…. See the tweet below for reflections from me & other recent awardees about the impact of this award on our research!

Huge CONGRATS to 2 former University of Maryland ID Fellowship Program fellows elected as Fellows of IDSA this year!!! Jennifer Rittenhouse Cope CDC Clare Rock Clare Rock MD MS Johns Hopkins Division of Infectious Diseases #FIDSA University of Maryland School of Medicine IDSA #IDTwitter idsociety.org/news--publicat… via IDSA

ID in the News: Clare Rock MD MS says HR teams should be proactive in applying Covid-19 lessons to ongoing health and safety measures in the workplace. bit.ly/3eatQ4R via HR Brew ☕️

Morning Read: Clinical Decision Support Systems to Reduce Unnecessary Clostridioides difficile Testing Across Multiple Hospitals pubmed.ncbi.nlm.nih.gov/35100620/ #diagnostics #cdiff Clare Rock MD MS

Congrats to ⁦Patrick Forde⁩ on the Young Investigator Award ⁦ECOG-ACRIN Cancer Research Group⁩ Well deserved as he is changing the care for patients with thoracic malignancies!

Dr. Patrick Forde at #RomeLung23 discusses how PDL1 could influence perioperative immunotherapy for NSCLC. Do we need chemo for PDL1 high? (worth studying) Should we give neoadjuvant IO in PDL1 negative cases? (yes if giving chemo) #LCSM

Congratulations to Johns Hopkins Division of Infectious Diseases director Amita Gupta, named Johns Hopkins Medicine’s inaugural Florence Sabin Professor in Infectious Diseases, in honor of #DrFlorenceSabin (1871-1953), the med school’s 1st woman professor (1917) & 1st woman elected to National Academy of Sciences (1925).

Anyone following #esmo23 virtually or any insomniacs like myself, please join the outstanding Dr. Sarah E. Lochrin (& me, both from 🇮🇪!) as we discuss #mesothelioma in a tumor board format this Tuesday night 8pm US Eastern time (1-2am Wed Western Europe, 9am wed Aus/Asia). Mesothelioma Applied Research Foundation

#esmo23 returnees who need motivation to stay awake tonight and beat that jet lag will please see below 👇

Outstanding sessions at #asco25 on the challenges and opportunities for International Medical Graduates practising oncology in the United States. Great work being done by the #IMGOncCoP ⁦IMG Oncologists⁩

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6